Navigation Links
Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Date:2/11/2008

nitiate clinical trials for its first two FOBs in 2008, both of whose brand sales represent over $3 billion in current sales world wide. Members of Insmed's skilled biologics team have worked on over 50 therapeutic proteins. Their focused protein-based drug development backgrounds, coupled with the Company's FDA-approved protein manufacturing facility, and clinical and regulatory expertise, positions Insmed, upon the establishment of a regulatory pathway, to be an initial entrant into the U.S. FOBs market with a broad range of medicines following the expiration of patents covering the innovator products.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. Insmed has a state-of-the- art, FDA-approved biologic commercial manufacturing facility in Boulder, Colorado and a Corporate office in Richmond, Virginia. For more information, please visit http://www.insmed.com.

About Robert J. Shapiro

Robert J. Shapiro is the chairman of Sonecon, LLC, a private firm that advises U.S. and foreign businesses, governments and non-profit organizations. Dr. Shapiro has advised, among others, U.S. President Bill Clinton and British Prime Minister Tony Blair; private firms including Amgen, AT&T, Gilead Sciences, Google, MCI, Inc., SLM Corporation, Nordstjernan of Sweden, and Fujitsu of Japan; and non-profit organizations including the American Public Transportation Association, the Education Finance Council, BIO, and the U.S. Chamber of Commerce. He is also chairman of the Globalization Initiative of NDN, co-chair of the American Task Force Argentina, Policy Fellow of the Georgetown University School of Business, Senior Fellow of the Progressive Policy Institute (PPI), and a director of the Ax:son-Johnson Foundation in Sweden. From 1997 to 2001, Dr. Shapir
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.502 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
... Plasmid , Mini Kit , ... James Griffith and Kim Vollmer , James Griffith, ... Instruments, Biosytems Application Lab, Westbury, , NY , , ... , Cosmids are commonly used vectors in the lab, providing the ...
... , , , , Other important parameters for optimizing electroporation., , , , ... , , Pulse length , ... field pulses , Adjustment , of ... , Influence , of temperature , ...
Cached Biology Technology:Agrobacterium tumefaciens 2Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 2Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 3Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 4Isolation of Cosmids using Eppendorf's Perfectprep Plasmid , Mini Kit 5
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... SALT LAKE CITY A single organ may contain more ... that complicates prospects for using the versatile cells to replace ... new study from the laboratory of geneticist Mario Capecchi, the ... online issue of the journal Nature Genetics, Capecchi and geneticist ...
... challenges is to understand the design principles and origins ... on the evolutionary origins of the brain and how ... humans. The research suggests that it is not ... during evolution, increasingly sophisticated molecular processing of nerve impulses ...
... Communication,Intelligence Corporation (the "Company") (OTC Bulletin Board: ... business process,automation in the financial industry and the ... it has closed a financing, on,June 5, 2008, ... As part of the financing, the Company ...
Cached Biology News:Caution on stem cell therapy 2Caution on stem cell therapy 3Caution on stem cell therapy 4Origins of the brain 2Origins of the brain 3Communication Intelligence Corporation Closes $3.6 Million Financing 2Communication Intelligence Corporation Closes $3.6 Million Financing 3Communication Intelligence Corporation Closes $3.6 Million Financing 4
For microscopy...
... cDNA Synthesis and Labeling Kit generates labeled ... First unmodified cDNA is made via a ... an Oligo(dT) primer. Unlike other methods, there ... the reverse transcription reaction. This unmodified cDNA ...
... high quality microarray scanner based on patented confocal ... spatial resolution. The DNAscope LM is unique ... scanner that is upgradeable to a total of ... Includes control module (computer), monitor, and ...
AC input: 50-60 Hz 115-120 V...
Biology Products: